BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Apr 11, 2005
 |  BioCentury  |  Strategy

Combinature takes the natural path

After finding it hard to generate deals for its drug discovery platform - and harder still to fund its approach in today’s product-oriented environment - natural compound play Combinature Biopharm AG is moving into the product space with four preclinical compounds.

When Combinature (Berlin, Germany) was founded in 2000, its goal was to develop libraries of natural products that had been modified using the company’s combinatorial biosynthesis technology platform. The technology is able to mix and match genes from different gene clusters to create hybrid pathways that lead to the production of novel natural compounds and derivatives of known compounds.

The company raised E10 million ($8.8 million) in a series A round in 2000 and was able to close several R&D collaborations, among them with Aventis Pharma Deutschland GmbH, now part of sanofi-aventis Group (Euronext:SAN; SNY, Paris, France), specialty chemistry play Degussa AG (FSE:DGX, Frankfurt, Germany) and industrial enzymes specialist Novozymes...

Read the full 747 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >